

For patients 12 years of age and older living with anti-AChR or anti-MuSK antibody-positive **generalized myasthenia gravis (gMG)**



With IMAIFY® disease control can last

**as measured by improvement in daily function*
in a 24-week clinical study**



AChR=acetylcholine receptor; MuSK=muscle-specific tyrosine kinase.

*Measured using the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, which assesses the impact of gMG on 8 daily-function items that are typically affected in gMG. The average reduction from baseline to Weeks 22, 23, and 24 in MG-ADL total score was 4.7 for people taking IMAIFY + current gMG treatment and 3.3 for people taking placebo + current gMG treatment.



WHAT IS IMAIFY® (nipocalimab-aahu)?

IMAIFY® is a prescription medicine used to treat adults and children 12 years of age and older with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

It is not known if IMAIFY® is safe and effective in children under 12 years of age.

SELECTED IMPORTANT SAFETY INFORMATION

IMAIFY® is not for everyone; only your healthcare provider can decide if it's right for you. Do not use if you are allergic to IMAIFY®. Reactions have included angioedema and anaphylaxis. IMAIFY® is a prescription medicine that may cause serious side effects, including infections, allergic (hypersensitivity) reactions, and infusion-related reactions. People treated with IMAIFY® should not receive live vaccines. Please read the Important Safety Information throughout and the Medication Guide for IMAIFY® to learn more about these and other risks associated with IMAIFY®. Discuss any questions you have with your healthcare provider.

Please see full Prescribing Information.

With IMAAVY, patients experienced significant improvement in daily function* and muscle weakness†

In the clinical study, patients took IMAAVY + current gMG treatment (called "standard of care") or placebo + current gMG treatment.‡

Ask your healthcare provider about IMAAVY

Visit [IMAAVY.com](https://www.imaavy.com) or scan the code below to discover more about IMAAVY.



Data rates may apply.



gMG=generalized myasthenia gravis; MG-ADL=Myasthenia Gravis Activities of Daily Living; QMG=Quantitative Myasthenia Gravis.

*Measured using the MG-ADL scale, which assesses the impact of gMG on 8 daily-function items that are typically affected in gMG. The average reduction from baseline to Weeks 22, 23, and 24 in MG-ADL total score was 4.7 for people taking IMAAVY + current gMG treatment and 3.3 for people taking placebo + current gMG treatment.

†Measured using the QMG scale, which assesses muscle weakness based on 13 items. The average reduction from baseline to Weeks 22 and 24 in QMG score was 4.9 for people taking IMAAVY + current gMG treatment and 2.1 for people taking placebo + current gMG treatment.

‡This study included adult patients with anti-AChR or anti-MuSK antibody-positive gMG. Current therapies included acetylcholinesterase inhibitors, steroids, or non-steroidal immunosuppressive therapies, taken together or separately.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about IMAAVY®?

IMAAVY® is a prescription medicine that may cause serious side effects, including:

- **Infections** are a common side effect of IMAAVY® that can be serious. Receiving IMAAVY® may increase your risk of infection. Tell your healthcare provider right away if you have any of the following infection symptoms:
 - fever
 - chills
 - shivering
 - cough
 - sore throat
 - fever blisters
 - burning when you urinate

Please see Important Safety Information throughout and full Prescribing Information.



What could a change in score mean for me?

You and your healthcare provider likely discuss your MG-ADL score at most visits. There are 8 domains: talking, chewing, swallowing, breathing, brushing teeth or hair, rising from a chair, double vision, and eyelid droop.

You might think of your MG-ADL score like a golf score, where a lower total score is a good thing. If your MG-ADL score goes down even a point or two, it might mean your gMG symptoms related to items like chewing or breathing are less severe.

Your healthcare provider may also assess your QMG score at visits—which evaluates muscle weakness based on 13 items.

How could that impact your daily activities?

In a 24-week clinical study, patients taking **IMAAVY** experienced greater improvement than those taking placebo.

IMAAVY + current gMG treatment:

Improvement in daily function

4.7 average point improvement as measured by MG-ADL score

- Patients taking placebo + current gMG treatment experienced a 3.3-point improvement on average
- This was measured using results averaged from Weeks 22, 23, and 24 of the study compared to baseline.

IMAAVY + current gMG treatment:

Improvement in muscle weakness

4.9 average point improvement as measured by QMG score

- Patients taking placebo + current gMG treatment experienced a 2.1-point improvement on average
- This was measured using results averaged from Weeks 22 and 24 of the study compared to baseline.

Individual results may vary. Talk to your healthcare provider to see if IMAAVY is right for you.

IMPORTANT SAFETY INFORMATION (cont'd)

What is the most important information I should know about IMAAVY®? (cont'd)

- **Allergic (hypersensitivity) reactions** may happen during or up to a few weeks after your IMAAVY® infusion. Get emergency medical help right away if you get any of these symptoms during or after your IMAAVY® infusion:
 - a swollen face, lips, mouth, tongue, or throat
 - difficulty swallowing or breathing
 - itchy rash (hives)
 - chest pain or tightness

Please see Important Safety Information throughout and full [Prescribing Information](#).



What are the possible side effects of IMAAVY?

IMPORTANT SAFETY INFORMATION (cont'd) What is the most important information I should know about IMAAVY®? (cont'd)

The most common side effects in people with gMG treated with IMAAVY® include:

- infection in parts of your body that you use for breathing (respiratory tract infection)
- swelling in your hands, ankles, or feet (peripheral edema)
- muscle spasms

IMAAVY® may cause serious side effects, including:

- **Infections.** Infections are a common side effect of IMAAVY® that can be serious. Receiving IMAAVY® may increase your risk of infection. Tell your healthcare provider right away if you have any of the following symptoms of infection:
 - fevers
 - shivering
 - sore throat
 - burning when you urinate
 - chills
 - cough
 - fever blisters
- **Allergic (hypersensitivity) reactions.** Allergic reactions may happen during or up to a few weeks after your IMAAVY® infusion. Get emergency medical help right away if you get any of these symptoms during or after your IMAAVY® infusion, which may be part of a serious allergic reaction:
 - swelling of your face, lips, mouth, tongue, or throat
 - difficulty swallowing or breathing
 - itchy rash (hives)
 - chest pain or tightness
- **Infusion-related reactions.** Tell your healthcare provider right away if you get any of the following symptoms during or a few days after your infusion of IMAAVY®:
 - headache
 - nausea
 - dizziness
 - flu-like symptoms
 - rash
 - fatigue
 - chills
 - redness of skin

These are not all of the possible side effects of IMAAVY®. Call your doctor for medical advice about side effects. **You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.**

Do not receive IMAAVY® if you have a severe allergic reaction to nipocalimab-aahu or any of the ingredients in IMAAVY®. Reactions have included angioedema and anaphylaxis.



How IMAAVY works

IMAAVY is designed to reduce harmful IgG antibodies, including anti-AChR and anti-MuSK, by binding and blocking FcRn receptors

Neonatal fragment crystallizable receptor (FcRn) is a protein that can keep harmful IgG antibodies in your body longer.

This allows the harmful IgG antibodies to continue to attach to muscle receptors and interfere with the signals sent from nerves.

IMAAVY belongs to the FcRn blocker class of treatments.


Because IMAAVY binds and blocks FcRn receptors, harmful IgG antibodies, including anti-AChR and anti-MuSK, are reduced.

These antibodies can cause gMG symptoms.



Scan here to see how IMAAVY works.

Data rates may apply.



IgG=immunoglobulin G.

IMPORTANT SAFETY INFORMATION (cont'd)

What is the most important information I should know about IMAAVY®? (cont'd)

Before using IMAAVY®, tell your healthcare provider about all of your medical conditions, including if you:

- ever had an allergic reaction to IMAAVY®.
- have or had any recent infections or symptoms of infection.
- have recently received or are scheduled to receive an immunization (vaccine). People who take IMAAVY® should not receive live vaccines.
- are pregnant, plan to become pregnant, or are breastfeeding. It is not known whether IMAAVY® will harm your baby.

Pregnancy Safety Study. There is a pregnancy safety study for IMAAVY® if IMAAVY® is given during pregnancy or you become pregnant while receiving IMAAVY®. Your healthcare provider should report IMAAVY® exposure by contacting Janssen at 1-800-526-7736 or www.IMAAVY.com.

Please see Important Safety Information throughout and full Prescribing Information.



IMAAVY can help you manage gMG symptoms on a schedule you can plan around



AT LEAST A
15-min infusion
every **2 weeks**
(after your starter dose)
followed by 30 minutes
of monitoring

How IMAAVY is taken

IMAAVY is given by a healthcare professional as an intravenous (IV) infusion

At your first appointment, your healthcare provider will give you a starting dose of IMAAVY as an IV infusion lasting at least **30 minutes**. An IV infusion is given through a needle placed into your vein.

Two weeks later you will receive your next dose of IMAAVY infusion lasting at least **15 minutes**. Your following doses will be given every **2 weeks**.

After each dose, your healthcare provider will **monitor you for 30 minutes** to look for any signs or symptoms of an infusion-related or hypersensitivity reaction.*

Allergic reactions can happen during your IMAAVY infusion. Tell your healthcare provider right away if you get any of these symptoms during your IMAAVY infusion.

*If you have a reaction during your IMAAVY infusion, your healthcare provider may decide to administer IMAAVY more slowly or stop your infusion. If you miss a scheduled IMAAVY infusion, you should receive your next dose as soon as possible.

IMPORTANT SAFETY INFORMATION (cont'd)

What is the most important information I should know about IMAAVY®? (cont'd)

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of IMAAVY®?

IMAAVY® may cause serious side effects. See "What is the most important information I should know about IMAAVY®?"

The most common side effects of IMAAVY® include: respiratory tract infection, peripheral edema (swelling in your hands, ankles, or feet), and muscle spasms.

These are not all the possible side effects of IMAAVY®. Call your doctor for medical advice about side effects. **You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.**

Please see the full Prescribing Information and Medication Guide for IMAAVY® and discuss any questions you have with your doctor.

Dosage Form and Strengths: IMAAVY® is supplied as a 300 mg/1.62 mL and a 1,200 mg/6.5 mL (185 mg/mL) single-dose vial per carton for intravenous injection.

cp-509746v1

Please see Important Safety Information throughout and full Prescribing Information.



Where can you receive IMAAVY infusions?



Your healthcare provider may administer IMAAVY in their office.



An infusion service provider may be able to coordinate **at-home administration** of IMAAVY.



Some hospitals offer IMAAVY as an outpatient service.



You can receive IMAAVY at an **infusion center** that carries it.



Scan the QR code to locate an infusion center that may carry IMAAVY.

Data rates may apply.



WHAT IS IMAAVY® (nipocalimab-aahu)?

IMAAVY® is a prescription medicine used to treat adults and children 12 years of age and older with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

It is not known if IMAAVY® is safe and effective in children under 12 years of age.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about IMAAVY®?

IMAAVY® is a prescription medicine that may cause serious side effects, including:

- **Infections** are a common side effect of IMAAVY® that can be serious. Receiving IMAAVY® may increase your risk of infection. Tell your healthcare provider right away if you have any of the following infection symptoms:
 - fever
 - chills
 - shivering
 - cough
 - sore throat
 - fever blisters
 - burning when you urinate

Please see Important Safety Information throughout and full Prescribing Information.





Once you and your healthcare provider
have decided that IMAAVY is right for you

Cost Support to Help You Get Started and Stay on Track



Learn about cost support
options that could help make
your treatment more affordable



Commercial or Private Insurance?

IMAAYV withMe Savings Program

Pay as little as \$0 per infusion

Program provides 2 separate offerings:

- ✓ **Medicine Cost Support** for the cost of your IMAAYV medicine
- ✓ **Treatment Administration Cost Support** for certain IMAAYV infusion administration and related monitoring costs



Maximum program benefit per calendar year shall apply. Terms expire at the end of each calendar year. Offer subject to change or end without notice. Restrictions, including monthly maximums, may apply. See program requirements at IMAAYVwithMeSavings.com.

Simple ways to enroll:



Visit IMAAYVwithMe.com/signup



Text "SAVINGS" to 82503 (message and data rates may apply*)

*See Terms and Privacy Statement at JNJwithMe.com/Terms-Conditions-Mobile and JNJ.com/privacy-center.

The support and resources provided by IMAAYV withMe are not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.

Additional Affordability Support From Johnson & Johnson

Patient assistance is available if you are uninsured or if you have commercial, employer-sponsored, or government coverage that does not fully meet your needs. You may be eligible to receive your medicine from J&J at no cost for up to one year. You must meet the eligibility and income requirements for the Johnson & Johnson Patient Assistance Program. See terms and conditions at PatientAssistanceInfo.com/IMM or en español at PatientAssistanceInfo.com/IMM/ES.



Government-Funded Coverage?

| Affordability programs may be available

Want to learn more?

Visit JNJwithMe.com/IMAAVY to find a comprehensive list of affordability programs and contact information.

We can provide information about other resources that may be able to help with your out-of-pocket medicine costs for IMAAVY.



No Insurance?

| You may be eligible for support

Want to learn more?

Visit JNJwithMe.com/IMAAVY to view options available for you.

Additional Affordability Support From Johnson & Johnson

Patient assistance is available if you are uninsured or if you have commercial, employer-sponsored, or government coverage that does not fully meet your needs. You may be eligible to receive your medicine from J&J at no cost for up to one year. You must meet the eligibility and income requirements for the Johnson & Johnson Patient Assistance Program. See terms and conditions at PatientAssistanceInfo.com/IMM or en español at PatientAssistanceInfo.com/IMM/ES.



Get free, personalized support to help make it easier to start and stay on treatment

Whether you need help understanding how to get your prescription filled or finding cost support options to help you pay for your treatment, IMAAVY withMe has everything you may need to help you start and stay on track. For a comprehensive list of cost support options, visit [IMAAVYwithMe.com](https://www.imaavywithme.com).

IMAAVY withMe offers:

- A dedicated Nurse Navigator* who partners with you to prepare for infusions and helps solve treatment challenges
- Resources tailored to your needs—helpful tips, tools, and access to the Patient Portal
- Access and cost support to help you access and afford your IMAAVY
- Infusion support to learn what to expect during treatment and find a treatment site

* Nurse Navigators do not provide medical advice. Please ask your healthcare provider any questions you might have about your disease and treatment.

Sign up for support

Visit:
[IMAAVYwithMe.com/signup](https://www.imaavywithme.com/signup)

Call:
888-750-8733
Monday–Friday,
8:00 AM – 11:00 PM ET

The support and resources provided by IMAAVY withMe are not intended to provide medical advice, replace a treatment plan you receive from your healthcare provider or nurse, or serve as a reason for you to start or stay on treatment.

Information about your insurance coverage, cost support options, and treatment support is given to you by service providers for IMAAVY withMe. The information you get does not require you to use any Johnson & Johnson product.

Asking the right questions can help you and your healthcare provider find a gMG treatment that’s right for you

Your healthcare provider is here to help. Here are some questions to help guide you during your discussion.

Since your last visit, which gMG symptoms have been bothering you the most? _____

How do you feel about the current control of your gMG symptoms? _____

Have more questions? Print this page and use this space to write them down. _____

This image shows a single sheet of white paper with horizontal blue ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

Myasthenia Gravis Foundation of America (MGFA) Website

Visit the website of the largest, leading patient advocacy organization solely focused on myasthenia gravis.

Data rates may apply.

MGFA Website - MG Lexicon

Produced in collaboration with patients, medical professionals, and industry partners, this lexicon guide bridges the gap in terminology between healthcare providers and those affected by MG.

Data rates may apply.



imaavy®
(nipocalimab-aahu)

Discover what IMAAVY could do for you



Significant improvement

in daily function* and muscle weakness†



Disease control that lasts

as measured by improvement in daily function* in a 24-week clinical study‡

Talk to your healthcare provider about IMAAVY

Scan the QR code or visit [IMAAVY.com](https://www.imaavy.com) to learn more



Data rates may apply.

*Measured using the MG-ADL scale, which assesses the impact of gMG on 8 daily-function items that are typically affected in gMG. The average reduction from baseline to Weeks 22, 23, and 24 in MG-ADL total score was 4.7 for people taking IMAAVY + current gMG treatment and 3.3 for people taking placebo + current gMG treatment.

†Measured using the QMG scale, which assesses muscle weakness based on 13 items. The average reduction from baseline to Weeks 22 and 24 in QMG score was 4.9 for people taking IMAAVY + current gMG treatment and 2.1 for people taking placebo + current gMG treatment.

‡This study included adult patients with anti-AChR or anti-MuSK antibody-positive gMG. Current therapies included acetylcholinesterase inhibitors, steroids, or non-steroidal immunosuppressive therapies, taken together or separately.

WHAT IS IMAAVY® (nipocalimab-aahu)?

IMAAVY® is a prescription medicine used to treat adults and children 12 years of age and older with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

It is not known if IMAAVY® is safe and effective in children under 12 years of age.

SELECTED IMPORTANT SAFETY INFORMATION

IMAAVY® is not for everyone; only your healthcare provider can decide if it's right for you. Do not use if you are allergic to IMAAVY®. Reactions have included angioedema and anaphylaxis. IMAAVY® is a prescription medicine that may cause serious side effects, including infections, allergic (hypersensitivity) reactions, and infusion-related reactions. People treated with IMAAVY® should not receive live vaccines. Please read the Important Safety Information throughout and the Medication Guide for IMAAVY® to learn more about these and other risks associated with IMAAVY®. Discuss any questions you have with your healthcare provider.

Please see full [Prescribing Information](#).

© Johnson & Johnson and its affiliates 2026 05/26 cp-507135v2